{"url_path":"/sec/traw/8-k/2026-07-09/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-082250-index.html","accession_number":"0001104659-26-082250","cik":"0001130598","ticker":"TRAW","issuer_name":"Traws Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-082250-index.html","primary_entity_key":"0001130598","primary_entity_name":"Traws Pharma, Inc."},"word_count":84,"has_tables":true,"body_markdown":"**Item 9.01 Financial\nStatements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit No.**\n \n**Description**\n\n[10.1](tm2620113d1_ex10-1.htm)\n \n[First Amendment to the Traws Pharma,\nInc. 2021 Incentive Compensation Plan.](tm2620113d1_ex10-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded\nwithin the inline XBRL Document).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly\nauthorized.\n\n \n\nDate: July 9, 2026\n**TRAWS PHARMA, INC.**\n\n \n \n\n \nBy:\n/s/ Charles Parker\n\n \n \nCharles Parker\n\n \n \nChief Financial Officer"}